Skip to main content
CHRS logo

CHRS

Coherus Oncology, Inc.

$0.37

3.90%

Trade Ideas Performance

Latest Closed Trade Idea

$0.37

3.90%
Loading...
We are loading your data. Please wait a moment.

Sentiment

News

10

Social

0

About

Events of Coherus Oncology, Inc. (CHRS)

In the past six months, Coherus Oncology reported Q2 2026 adjusted EPS of -$0.19, beating consensus, though revenue of $14.31 million missed estimates, leading to a 12.8% stock decline the next day despite a 15% quarter-over-quarter increase in LOQTORZI net sales. The company announced compelling interim clinical data in October 2026 from its TREGCHECK development program for tagmokitug in esophageal cancer, showing a 75% confirmed response rate, and management expected further clinical data updates in Q4 2026, including mature tagmokitug head/neck data and initial hepatocellular carcinoma program results. Coherus Oncology received a Nasdaq deficiency notice due to its shares closing below $1.00 for an extended period. The stock's 52-week range has been between $0.73 and $2.62, trading near the lower end in late October 2026. The company was expected to report its Q3 2026 financial results on November 9, 2026.

FAQ

Related Assets

Price action provided by Massive. Fundamentals, news and corporate events provided by FactSet. NLP support provided by Perplexity & Gemini. All data is provided for informational purposes only.

Make every trade make sense.

Sign up free. No card required. Three trade ideas a day, the AI analyst, the community - on us.

Get started for FREE (opens in new tab)
Edge Hound mobile app preview on iPhone

Join us and trade with people
who think like you.

The Edge Hound Discord is where serious self-directed investors talk strategy, share setups, and learn from each other. Free to join with any plan - including Free.

Free to join with any plan - including Free.

Join our Discord community (opens in new tab)